186 related articles for article (PubMed ID: 36781585)
1. Plasma Biomarkers and Positron Emission Tomography Tau Pathology in Progressive Supranuclear Palsy.
Huang SY; Chen SF; Cui M; Zhao M; Shen XN; Guo Y; Zhang YR; Zhang W; Wang HF; Huang YY; Cheng W; Zuo CT; Dong Q; Yu JT
Mov Disord; 2023 Apr; 38(4):676-682. PubMed ID: 36781585
[TBL] [Abstract][Full Text] [Related]
2. Phosphorylated α-synuclein and phosphorylated tau-protein in sural nerves may contribute to differentiate Parkinson's disease from multiple system atrophy and progressive supranuclear paralysis.
Rong Z; Shen F; Wang Y; Sun L; Wu J; Zhang H; Yuan Y; Jiang W; Li X; Ji P; Zhang K
Neurosci Lett; 2021 Jun; 756():135964. PubMed ID: 34022266
[TBL] [Abstract][Full Text] [Related]
3. Differential levels of plasma biomarkers of neurodegeneration in Lewy body dementia, Alzheimer's disease, frontotemporal dementia and progressive supranuclear palsy.
Chouliaras L; Thomas A; Malpetti M; Donaghy P; Kane J; Mak E; Savulich G; Prats-Sedano MA; Heslegrave AJ; Zetterberg H; Su L; Rowe JB; O'Brien JT
J Neurol Neurosurg Psychiatry; 2022 Jun; 93(6):651-658. PubMed ID: 35078917
[TBL] [Abstract][Full Text] [Related]
4. Systematic Assessment of 10 Biomarker Candidates Focusing on α-Synuclein-Related Disorders.
Schulz I; Kruse N; Gera RG; Kremer T; Cedarbaum J; Barbour R; Zago W; Schade S; Otte B; Bartl M; Hutten SJ; Trenkwalder C; Mollenhauer B
Mov Disord; 2021 Dec; 36(12):2874-2887. PubMed ID: 34363416
[TBL] [Abstract][Full Text] [Related]
5. Diagnosis Across the Spectrum of Progressive Supranuclear Palsy and Corticobasal Syndrome.
Jabbari E; Holland N; Chelban V; Jones PS; Lamb R; Rawlinson C; Guo T; Costantini AA; Tan MMX; Heslegrave AJ; Roncaroli F; Klein JC; Ansorge O; Allinson KSJ; Jaunmuktane Z; Holton JL; Revesz T; Warner TT; Lees AJ; Zetterberg H; Russell LL; Bocchetta M; Rohrer JD; Williams NM; Grosset DG; Burn DJ; Pavese N; Gerhard A; Kobylecki C; Leigh PN; Church A; Hu MTM; Woodside J; Houlden H; Rowe JB; Morris HR
JAMA Neurol; 2020 Mar; 77(3):377-387. PubMed ID: 31860007
[TBL] [Abstract][Full Text] [Related]
6. Increased cerebrospinal fluid levels of neurofilament protein in progressive supranuclear palsy and multiple-system atrophy compared with Parkinson's disease.
Holmberg B; Rosengren L; Karlsson JE; Johnels B
Mov Disord; 1998 Jan; 13(1):70-7. PubMed ID: 9452329
[TBL] [Abstract][Full Text] [Related]
7. A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes.
Magdalinou NK; Paterson RW; Schott JM; Fox NC; Mummery C; Blennow K; Bhatia K; Morris HR; Giunti P; Warner TT; de Silva R; Lees AJ; Zetterberg H
J Neurol Neurosurg Psychiatry; 2015 Nov; 86(11):1240-7. PubMed ID: 25589779
[TBL] [Abstract][Full Text] [Related]
8. Magnetic Resonance Imaging and Neurofilament Light in the Differentiation of Parkinsonism.
Archer DB; Mitchell T; Burciu RG; Yang J; Nigro S; Quattrone A; Quattrone A; Jeromin A; McFarland NR; Okun MS; Vaillancourt DE
Mov Disord; 2020 Aug; 35(8):1388-1395. PubMed ID: 32357259
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic value of isolated plasma biomarkers and its combination in neurodegenerative dementias: A multicenter cohort study.
Chen Y; Wang Y; Tao Q; Lu P; Meng F; Zhuang L; Qiao S; Zhang Y; Luo B; Liu Y; Peng G
Clin Chim Acta; 2024 May; 558():118784. PubMed ID: 38588788
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic value of plasma p-tau181, NfL, and GFAP in a clinical setting cohort of prevalent neurodegenerative dementias.
Baiardi S; Quadalti C; Mammana A; Dellavalle S; Zenesini C; Sambati L; Pantieri R; Polischi B; Romano L; Suffritti M; Bentivenga GM; Randi V; Stanzani-Maserati M; Capellari S; Parchi P
Alzheimers Res Ther; 2022 Oct; 14(1):153. PubMed ID: 36221099
[TBL] [Abstract][Full Text] [Related]
11. Regional brain volumes distinguish PSP, MSA-P, and PD: MRI-based clinico-radiological correlations.
Paviour DC; Price SL; Jahanshahi M; Lees AJ; Fox NC
Mov Disord; 2006 Jul; 21(7):989-96. PubMed ID: 16602104
[TBL] [Abstract][Full Text] [Related]
12. Clinical value of CSF amyloid-beta-42 and tau proteins in Progressive Supranuclear Palsy.
Schirinzi T; Sancesario GM; Di Lazzaro G; Scalise S; Colona VL; Imbriani P; Mercuri NB; Bernardini S; Lang AE; Pisani A
J Neural Transm (Vienna); 2018 Sep; 125(9):1373-1379. PubMed ID: 29948175
[TBL] [Abstract][Full Text] [Related]
13. Systematic assessment of plasma biomarkers in spinocerebellar ataxia.
Shen XN; Wu KM; Huang YY; Guo Y; Huang SY; Zhang YR; Chen SF; Wang HF; Zhang W; Cheng W; Cui M; Dong Q; Yu JT
Neurobiol Dis; 2023 Jun; 181():106112. PubMed ID: 37003406
[TBL] [Abstract][Full Text] [Related]
14. Development and validation of the automated imaging differentiation in parkinsonism (AID-P): a multicentre machine learning study.
Archer DB; Bricker JT; Chu WT; Burciu RG; McCracken JL; Lai S; Coombes SA; Fang R; Barmpoutis A; Corcos DM; Kurani AS; Mitchell T; Black ML; Herschel E; Simuni T; Parrish TB; Comella C; Xie T; Seppi K; Bohnen NI; Müller ML; Albin RL; Krismer F; Du G; Lewis MM; Huang X; Li H; Pasternak O; McFarland NR; Okun MS; Vaillancourt DE
Lancet Digit Health; 2019 Sep; 1(5):e222-e231. PubMed ID: 33323270
[TBL] [Abstract][Full Text] [Related]
15. Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders.
Hall S; Öhrfelt A; Constantinescu R; Andreasson U; Surova Y; Bostrom F; Nilsson C; Håkan W; Decraemer H; Någga K; Minthon L; Londos E; Vanmechelen E; Holmberg B; Zetterberg H; Blennow K; Hansson O
Arch Neurol; 2012 Nov; 69(11):1445-52. PubMed ID: 22925882
[TBL] [Abstract][Full Text] [Related]
16. Differentiation of progressive supranuclear palsy: clinical, imaging and laboratory tools.
Liscic RM; Srulijes K; Gröger A; Maetzler W; Berg D
Acta Neurol Scand; 2013 May; 127(5):362-70. PubMed ID: 23406296
[TBL] [Abstract][Full Text] [Related]
17. PSP as distinguished from CBD, MSA-P and PD by clinical and imaging differences at an early stage.
Kurata T; Kametaka S; Ohta Y; Morimoto N; Deguchi S; Deguchi K; Ikeda Y; Takao Y; Ohta T; Manabe Y; Sato S; Abe K
Intern Med; 2011; 50(22):2775-81. PubMed ID: 22082889
[TBL] [Abstract][Full Text] [Related]
18. Novel decision algorithm to discriminate parkinsonism with combined blood and imaging biomarkers.
Mangesius S; Mariotto S; Ferrari S; Pereverzyev S; Lerchner H; Haider L; Gizewski ER; Wenning G; Seppi K; Reindl M; Poewe W
Parkinsonism Relat Disord; 2020 Aug; 77():57-63. PubMed ID: 32622301
[TBL] [Abstract][Full Text] [Related]
19. Diffusion-weighted magnetic resonance imaging differentiates Parkinsonian variant of multiple-system atrophy from progressive supranuclear palsy.
Paviour DC; Thornton JS; Lees AJ; Jäger HR
Mov Disord; 2007 Jan; 22(1):68-74. PubMed ID: 17089396
[TBL] [Abstract][Full Text] [Related]
20. Development and Validation of Automated Magnetic Resonance Parkinsonism Index 2.0 to Distinguish Progressive Supranuclear Palsy-Parkinsonism From Parkinson's Disease.
Quattrone A; Bianco MG; Antonini A; Vaillancourt DE; Seppi K; Ceravolo R; Strafella AP; Tedeschi G; Tessitore A; Cilia R; Morelli M; Nigro S; Vescio B; Arcuri PP; De Micco R; Cirillo M; Weis L; Fiorenzato E; Biundo R; Burciu RG; Krismer F; McFarland NR; Mueller C; Gizewski ER; Cosottini M; Del Prete E; Mazzucchi S; Quattrone A
Mov Disord; 2022 Jun; 37(6):1272-1281. PubMed ID: 35403258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
